Radiopharm Theranostics Limited Stock Performance
| RADX Stock | 4.40 0.14 3.08% |
The company holds a Beta of 0.7, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Radiopharm Theranostics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Radiopharm Theranostics is expected to be smaller as well. At this point, Radiopharm Theranostics has a negative expected return of -0.0379%. Please make sure to check Radiopharm Theranostics' potential upside, and the relationship between the total risk alpha and kurtosis , to decide if Radiopharm Theranostics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Radiopharm Theranostics Limited has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Radiopharm Theranostics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Radiopharm |
Radiopharm Theranostics Relative Risk vs. Return Landscape
If you would invest 518.00 in Radiopharm Theranostics Limited on August 18, 2025 and sell it today you would lose (78.00) from holding Radiopharm Theranostics Limited or give up 15.06% of portfolio value over 90 days. Radiopharm Theranostics Limited is currently does not generate positive expected returns and assumes 6.7115% risk (volatility on return distribution) over the 90 days horizon. In different words, 60% of pink sheets are less volatile than Radiopharm, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Radiopharm Theranostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Radiopharm Theranostics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Radiopharm Theranostics Limited, and traders can use it to determine the average amount a Radiopharm Theranostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0057
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RADX |
Estimated Market Risk
| 6.71 actual daily | 60 60% of assets are less volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Radiopharm Theranostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Radiopharm Theranostics by adding Radiopharm Theranostics to a well-diversified portfolio.
Things to note about Radiopharm Theranostics performance evaluation
Checking the ongoing alerts about Radiopharm Theranostics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Radiopharm Theranostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Radiopharm Theranostics generated a negative expected return over the last 90 days | |
| Radiopharm Theranostics has high historical volatility and very poor performance |
- Analyzing Radiopharm Theranostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Radiopharm Theranostics' stock is overvalued or undervalued compared to its peers.
- Examining Radiopharm Theranostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Radiopharm Theranostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Radiopharm Theranostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Radiopharm Theranostics' pink sheet. These opinions can provide insight into Radiopharm Theranostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Radiopharm Pink Sheet Analysis
When running Radiopharm Theranostics' price analysis, check to measure Radiopharm Theranostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Radiopharm Theranostics is operating at the current time. Most of Radiopharm Theranostics' value examination focuses on studying past and present price action to predict the probability of Radiopharm Theranostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Radiopharm Theranostics' price. Additionally, you may evaluate how the addition of Radiopharm Theranostics to your portfolios can decrease your overall portfolio volatility.